The FDA has approved the first generic version of Tamiflu (oseltamivir phosphate).
Tamiflu is most commonly used to treat influenza A and B in patients aged 2 weeks and older who have experienced flu symptoms for 48 hours or less; the medication can also be used to prevent the flu in patients 1 year and older. The FDA is unsure whether oseltamivir phosphate is effective in patients who began treatment 2 days after initial symptoms developed, or in patients who have weakened immune systems.
The most common side effects of oseltamivir phosphate are nausea and vomiting.
“Patients must use oseltamivir phosphate as directed by their healthcare provider,” noted the FDA. “Oseltamivir phosphate does not take the place of receiving a flu vaccination.”
- The FDA approves first generic version of widely used influenza drug, Tamiflu [news release]. Silver Spring, MD: US Food and Drug Administration. Published August 4, 2016. Accessed August 10, 2016.